The influence of successful prophylactic drug treatment on cognitive dysfunction in XXXX .

@entity1 @entity162 @entity308 @entity1091 @entity2049
BACKGROUND: Cognitive variables such as negative self-evaluations have been discussed as vulnerability factors for @entity308 . In the context of @entity162 dysfunctional cognitive structures have received little interest as these @entity1 seem to be less disturbed during the euthymic interval than @entity1 with @entity308 . METHODS: In the present study, the self-esteem of remitted @entity1 with DSM-III-R diagnosis of @entity308 (n=20), @entity162 (n=20) and healthy controls (n=20) was measured with the Frankfurt Self-concept Scale (FSKN). RESULTS: 1) Statistical analysis by analysis of variance (ANOVA) showed no significant differences as to age, sex, etc. between the psychiatric groups. The clinical groups showed lower self-esteem ratings in comparison to healthy controls. 2) Four groups (T1-T4) of remitted @entity1 with @entity162 (20 in each group) were successfully maintained on mood stabilizers ( @entity1091 or @entity2049 ) and classified by the duration of their episode-free period. T1 included those who were episode-free for only the week before discharge from hospital. T2 were symptom-free for <30 months. T3 were episode-free for >30 months and <60 months. T4 were episode-free for >60 months. The comparison of their FSKN self-esteem ratings by ANOVA suggests that self-esteem improves during successful prophylactic treatment. A posteriori contrasts indicate a normalized self-esteem after a bipolar episode-free period of at least 47 months. CONCLUSIONS: Dysfunctional cognitions can be demonstrated in unipolar as well as in bipolar @entity1 . Successful episode-preventive medication with mood stabilizers seems to counteract lowered self-esteem. Adjunctive cognitive therapy might help to optimize the long-term course of @entity162 .
